evofloxacin and bismuth-based regimens for H. pylori eradicatio
Phase 4
Recruiting
- Registration Number
- IRCT20191010045053N1
- Lead Sponsor
- Zakho University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
The inclusion criteria for recruiting subjects in this study will be H. pylori positivity, adults older than 18 years and agreeing to be recruited.
Exclusion Criteria
Patients with prior history of antibiotics use, and those who will not agree are excluded.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gender and age did not influence the eradication rate. Timepoint: First group (LBR) will receive levofloxacin 500mg one time a day, amoxicillin 1000mg two times a day and omeprazole 20mg two times a day for two weeks. The second group (TMB) will receive bismuth subcitrate 140mg, metronidazole 125 mg, and tetracycline 125 mg plus omeprazole 20mg twice per day for 10 days. 28 days after the completion of treatment course, H. pylori eradication will be evaluated by the 14C urease breath test (UBT). Method of measurement: The status of infection are proven by performing slide urease reaction during endoscopy or by UBT. All subjects then are assessed using the 14Carbon urea breath test after treatment conclusion.
- Secondary Outcome Measures
Name Time Method